GRAIL develops multi-cancer early detection tests that use cell-free DNA analysis to detect signals of 50+ cancer types from a single blood draw.
GRAIL is a healthcare company founded in 2016 as an Illumina spinout focused on developing multi-cancer early detection tests using liquid biopsy technology. The company's flagship product Galleri is a blood test that analyzes cell-free DNA methylation patterns to detect cancer signals from over 50 cancer types, many of which lack standard screening tests, enabling detection at early stages when treatment is most effective. GRAIL raised over $3.5B from investors including Amazon and Bristol Myers Squibb and was reacquired by Illumina in 2021 before being spun off again in 2024 as an independent public company following regulatory complications. Galleri has been launched commercially and is being evaluated in large clinical studies including the NHS-Galleri trial in the UK enrolling 140,000 participants. The company represents a transformative approach to oncology that could shift cancer care from reactive treatment toward proactive screening. GRAIL's technology addresses a massive unmet need given that the majority of cancers are diagnosed at late stages when outcomes are poor.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.